{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:29:50Z","timestamp":1771867790575,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,5]],"date-time":"2014-01-05T00:00:00Z","timestamp":1388880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00702-013-1155-1","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T15:34:09Z","timestamp":1388849649000},"page":"643-648","source":"Crossref","is-referenced-by-count":12,"title":["Levodopa-related cysteinyl\u2013glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson\u2019s disease patients"],"prefix":"10.1007","volume":"121","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Muhlack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,5]]},"reference":[{"key":"1155_CR1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.neuint.2012.12.004","volume":"62","author":"GF Allen","year":"2013","unstructured":"Allen GF, Ullah Y, Hargreaves IP, Land JM, Heales SJ (2013) Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson\u2019s and other dopamine deficiency states. Neurochem Int 62:684\u2013694","journal-title":"Neurochem Int"},{"key":"1155_CR2","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"1155_CR3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00210-005-0025-2","volume":"372","author":"Y Fujita","year":"2006","unstructured":"Fujita Y, Izawa Y, Ali N, Kanematsu Y, Tsuchiya K, Hamano S, Tamaki T, Yoshizumi M (2006) Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol 372:257\u2013266","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1155_CR4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.neuint.2009.07.009","volume":"55","author":"M Inden","year":"2009","unstructured":"Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T (2009) Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochem Int 55:760\u2013767","journal-title":"Neurochem Int"},{"key":"1155_CR5","doi-asserted-by":"crossref","first-page":"e66639","DOI":"10.1371\/journal.pone.0066639","volume":"8","author":"C Jugel","year":"2013","unstructured":"Jugel C, Ehlen F, Taskin B, Marzinzik F, M\u00fcller T, Klostermann F (2013) Neuropathy in Parkinson\u2019s disease patients with intestinal levodopa infusion versus oral drugs. PLoS ONE 8:e66639","journal-title":"PLoS ONE"},{"key":"1155_CR6","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0024-3205(03)00174-7","volume":"72","author":"I Miklya","year":"2003","unstructured":"Miklya I, Knoll B, Knoll J (2003) A pharmacological analysis elucidating why, in contrast to (\u2212)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Life Sci 72:2641\u20132648","journal-title":"Life Sci"},{"key":"1155_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","volume":"20","author":"JW Miller","year":"1997","unstructured":"Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA (1997) Effect of l-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55\u201366","journal-title":"Clin Neuropharmacol"},{"key":"1155_CR8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/17425255.2011.575779","volume":"7","author":"T M\u00fcller","year":"2011","unstructured":"M\u00fcller T (2011) Motor complications, levodopa metabolism and progression of Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 7:847\u2013855","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1155_CR9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/ern.13.50","volume":"13","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T (2013) Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson\u2019s disease. Expert Rev Neurother 13:707\u2013718","journal-title":"Expert Rev Neurother"},{"key":"1155_CR10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/mds.22482","volume":"24","author":"T M\u00fcller","year":"2009","unstructured":"M\u00fcller T, Kuhn W (2009) Cysteine elevation in levodopa-treated patients with Parkinson\u2019s disease. Mov Disord 24:929\u2013932","journal-title":"Mov Disord"},{"key":"1155_CR11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/mds.23384","volume":"26","author":"T M\u00fcller","year":"2011","unstructured":"M\u00fcller T, Muhlack S (2011) Cysteinyl\u2013glycine reduction as marker for levodopa-induced oxidative stress in Parkinson\u2019s disease patients. Mov Disord 26:543\u2013546","journal-title":"Mov Disord"},{"key":"1155_CR100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2012.05.054","volume":"521","author":"T M\u00fcller","year":"2012","unstructured":"M\u00fcller T, Muhlack S (2012)\u00a0Cysteine decrease following acute Levodopa intake in patients with Parkinson\u2019s disease. Neurosci Lett 521(1):37\u201339","journal-title":"Neurosci Lett"},{"key":"1155_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002826-200603000-00001","volume":"29","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, Goetze O (2006) Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 29:61\u201367","journal-title":"Clin Neuropharmacol"},{"key":"1155_CR13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00702-007-0773-x","volume":"114","author":"T M\u00fcller","year":"2007","unstructured":"M\u00fcller T, Ander L, Kolf K, Woitalla D, Muhlack S (2007) Comparison of 200\u00a0mg retarded release levodopa\/carbidopa\u2014with 150\u00a0mg levodopa\/carbidopa\/entacapone application: pharmacokinetics and efficacy in patients with Parkinson\u2019s disease. J Neural Transm 114:1457\u20131462","journal-title":"J Neural Transm"},{"key":"1155_CR14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.parkreldis.2013.02.006","volume":"19","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A (2013) Peripheral neuropathy in Parkinson\u2019s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19:501\u2013507","journal-title":"Parkinsonism Relat Disord"},{"key":"1155_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","author":"NINDS NET-PD Investigators","year":"2007","unstructured":"NINDS NET-PD Investigators (2007) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:20\u201328","journal-title":"Neurology"},{"key":"1155_CR16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653\u20131661","journal-title":"JAMA"},{"key":"1155_CR17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1468-1331.1999.tb00007.x","volume":"6","author":"H Przuntek","year":"1999","unstructured":"Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, Rinne U, Schimrigk K, Schnitker J, Vogel HP (1999) SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 6:141\u2013150","journal-title":"Eur J Neurol"},{"key":"1155_CR18","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2174\/0929867043364775","volume":"11","author":"P Riederer","year":"2004","unstructured":"Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033\u20132043","journal-title":"Curr Med Chem"},{"key":"1155_CR19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.parkreldis.2007.06.015","volume":"13","author":"P Riederer","year":"2007","unstructured":"Riederer P, Gerlach M, M\u00fcller T, Reichmann H (2007) Relating mode of action to clinical practice: dopaminergic agents in Parkinson\u2019s disease. Parkinsonism Relat Disord 13:466\u2013479","journal-title":"Parkinsonism Relat Disord"},{"key":"1155_CR20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","volume":"12","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K (2013) Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12:747\u2013755","journal-title":"Lancet Neurol"},{"key":"1155_CR21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2005.02.002","volume":"107","author":"CW Shults","year":"2005","unstructured":"Shults CW (2005) Therapeutic role of coenzyme Q(10) in Parkinson\u2019s disease. Pharmacol Ther 107:120\u2013130","journal-title":"Pharmacol Ther"},{"key":"1155_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","volume":"62","author":"M Smeyne","year":"2013","unstructured":"Smeyne M, Smeyne RJ (2013) Glutathione metabolism and Parkinson\u2019s disease. Free Radic Biol Med 62:13\u201325","journal-title":"Free Radic Biol Med"},{"key":"1155_CR23","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25:2649\u20132653","journal-title":"Mov Disord"},{"key":"1155_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93\u2013101","journal-title":"Ann Neurol"},{"key":"1155_CR25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.biopha.2008.01.017","volume":"62","author":"GD Zeevalk","year":"2008","unstructured":"Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson\u2019s disease: is this the elephant in the room? Biomed Pharmacother 62:236\u2013249","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1155-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-1155-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1155-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:30:27Z","timestamp":1559104227000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-1155-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,5]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-1155-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,5]]}}}